Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage

Mentis, Alexios‐Fotios A.; Dardiotis, Efthimios

doi:10.3389/fonc.2019.00090

Cited by 7 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Eradication of H. pylori improves gastrointestinal (GI) ulcers and decreases the recurrence of this infection, effectively preventing the development of gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma (MALT). 3,4 H. pylori-associated inflammation triggers ulceration and also non-GI diseases such as atherosclerosis. 5 On the other hand, evidence from in vitro and preclinical studies have suggested that benzimidazole derivatives could repress H. pylori-mediated inflammation.…”

Section: Introductionmentioning

confidence: 99%

Benzimidazole derivatives: A versatile scaffold for drug development against Helicobacter pylori‐related diseases

Rostami

Haddadi

2022

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a microaerophilic gastric pathogen and a major contributor to chronic atrophic gastritis, peptic ulcer, and gastric malignancies. The increasing prevalence of H. pylori infection and its related diseases, such as gastric cancer (GC), motivates medicinal chemists to seek for more effective multi‐targeting drugs to prevent and treat H. pylori‐related clinical complications. Benzimidazole, a hetero‐aromatic bicyclic ring compound, has claimed a prominent role in medicinal chemistry owing to its broad range of biological activities, including antibacterial, antiviral, antidiabetic, and anticancer activities. Studies highlight the promising therapeutic potential of benzimidazole derivatives in the treatment of H. pylori‐related clinical complications such as gastric infection, gastritis, peptic ulcer, and GC. Accordingly, we here aimed to scrutinize the role of active molecules of benzimidazole derivatives as potential antibacterial, anti‐urease, anti‐inflammatory, anti‐ulcerative, and anticancer agents, which are expected to find their ways to the clinical setting sooner or later. Due to the role of structural moieties in determining the biological behaviors of benzimidazole derivatives, we explored the structure–activity relationship (SAR) of these compounds to further expand the scope of design of and research on new drugs against H. pylori‐related diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Benzimidazole derivatives: A versatile scaffold for drug development against Helicobacter pylori‐related diseases

Rostami

Haddadi

2022

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…While the inhibition of HIWI expression decreases the proliferation of gastric cancer cells (although potential effects of H. pylori, the major risk factor of gastric cancer (Mentis and Dardiotis, 2019), on PIWI levels have not yet been investigated, to our knowledge ), its high expression induces apoptosis in leukemia cell lines (Liu et al, 2006, Sharma et al, 2001. Hence, some included studies hypothesized that there is a U-shaped relationship between PIWI expression and survival.…”

Section: Discussionmentioning

confidence: 96%

PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis

Mentis

Dardiotis²,

Romas

et al. 2019

Cell. Mol. Life Sci.

Self Cite

View full text Add to dashboard Cite

Background: PIWI proteins, which interact with piRNAs, are implicated in stem cell and germ cell regulation, but have been detected in various cancers, as well.Objectives: In this systematic review, we explored, for the first time in the literature (to our knowledge), the association between prognosis in patients with cancer and intratumoral expression of PIWI proteins.Data sources: PubMed, Embase and Web of Knowledge databases were searched for the relevant cohort studies. Study eligibility criteria:Prospective or retrospective cohort studies investigating the association of intratumoral mRNA or protein expression of different types of PIWI proteins with survival, metastasis or recurrence of various types of cancers in the systematic review. Exclusion of cross-sectional studies, of studies on the prognostic value of genetic polymorphism of PIWI genes, of studies re-analyzed previously published databases, and of conference abstracts and non-English articles.Participants: Twenty-six studies with 4,299 participants were included in the systematic review.Interventions: Pooled Hazard Ratios (HRs) and their 95% Confidence Intervals (CIs) were calculated for different PIWI proteins separately, by pooling of log of the calculated HRs using the random-effects model.Study appraisal and synthesis methods: Data extraction was performed using a pre-designed form and quality of the studies was assessed using REMARK criteria. Heterogeneity assessed using the I 2 index and the Cochran Q test. Publication bias assessed using funnel plots and Egger's regression. Results:The pooled HR of mortality in high compared to low expression of HIWI, HILI and PIWIL4 was 1.87 (CI95%: 1.31-2.66, p < 0.05), 1.09 (CI95%: 0.58-2.07, p = 0.79) and 0.44 (CI95%: 0.25-0.76, p < 0.05), respectively. The pooled HR of recurrence in in high compared to low expression of HIWI and

show abstract

“…These results imply that the risk posed by having a family history of gastric cancer can be mitigated by addressing an environmental (in this case, microbial) factor [ 7 ]. Nonetheless, they should be interpreted with caution, especially upon considering some methodological caveats in this study, which diminish their broader clinical usefulness (as observed in other H. pylori -related studies [ 9 ]). Specifically, the family history of gastric cancer was defined as having at least one first-degree relative with gastric cancer whose diagnosis had been histologically confirmed [ 7 ].…”

mentioning

confidence: 87%

Merging Helicobacter pylori eradication and family history-based genetic counseling in patients with gastric cancer: towards an overarching approach in clinical practice

Mentis

Rokkas

2021

aog

View full text Add to dashboard Cite

Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage

Cited by 7 publications

References 33 publications

Benzimidazole derivatives: A versatile scaffold for drug development against Helicobacter pylori‐related diseases

Benzimidazole derivatives: A versatile scaffold for drug development against Helicobacter pylori‐related diseases

PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis

Merging Helicobacter pylori eradication and family history-based genetic counseling in patients with gastric cancer: towards an overarching approach in clinical practice

Contact Info

Product

Resources

About